Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
25%
Ph not_applicable
1
25%
Ph phase_4
2
50%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)

Trials by Status

unknown125%
recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
completednot_applicable

Weak Pulse at Yang and Wiry Pulse at Yin Theory

NCT07378228
recruitingphase_4

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753
completedphase_4

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

NCT05238012
unknownphase_1

COVID-19 Vaccination Detoxification in LDL-C

NCT05839236

Clinical Trials (4)

Showing 4 of 4 trials
NCT07378228Not Applicable

Weak Pulse at Yang and Wiry Pulse at Yin Theory

Completed
NCT05641753Phase 4

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Recruiting
NCT05238012Phase 4

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

Completed
NCT05839236Phase 1

COVID-19 Vaccination Detoxification in LDL-C

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4